Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLUTE phase 3 trial of benralizumab in eosinophilic COPD with frequent exacerbations
CTR20211104Phase 3Completed
- Sponsor
- Catalent
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benralizumab in chronic obstructive pulmonary disease (COPD), sponsored by Catalent. Started Feb 2022; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20211104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211104.